Form 4: ZyVersa Therapeutics CFO Discloses Previously Unreported Stock Option Grant

Peter Wolfe, CFO of ZyVersa Therapeutics, reports a previously unreported stock option grant received in May 2023.

Summary

• Peter Wolfe, the Chief Financial Officer of ZyVersa Therapeutics, filed a Form 4 to report a previously unreported stock option grant.
• The grant was initially awarded on May 24, 2023, for 715 stock options with an exercise price of $152.46.
• The options vest annually in three equal installments starting on May 24, 2024, and expire on May 24, 2033.
• The reporting delay was attributed to an administrative oversight.
• The share and dollar amounts reflect a 1-for-35 reverse stock split on December 4, 2023, and a 1-for-10 reverse stock split on April 25, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as it primarily reports a past administrative oversight and a stock option grant. The oversight is a minor negative, but the grant itself is a standard part of executive compensation.

Negatives

• The late reporting of the stock option grant indicates an administrative oversight, which could raise concerns about internal controls.

Risks

• The administrative oversight leading to the delayed reporting could indicate weaknesses in the company's internal controls and compliance procedures.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The late filing, however, is unusual.

Stakeholder Impact

• Shareholders may be concerned about the administrative oversight that led to the delayed reporting.

Key Dates

Keywords

Form 4, stock options, ZyVersa Therapeutics, Peter Wolfe, CFO, beneficial ownership, reverse stock split